235 related articles for article (PubMed ID: 31162261)
1. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
3. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
4. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
6.
Zhang J; Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Langbein T; Baum RP
J Nucl Med; 2019 Nov; 60(11):1579-1586. PubMed ID: 30850499
[TBL] [Abstract][Full Text] [Related]
7. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
8.
Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
[TBL] [Abstract][Full Text] [Related]
9.
Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of
Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
[No Abstract] [Full Text] [Related]
11. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
12. [
Boegemann M; Schrader AJ; Rahbar K
Urologe A; 2017 Nov; 56(11):1440-1444. PubMed ID: 28986618
[TBL] [Abstract][Full Text] [Related]
13. Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Zisser L; Yu J; Oszwald A; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat SF; Mitterhauser M; Vraka C; Hacker M; Haug AR; Rasul S
Nucl Med Commun; 2022 Nov; 43(11):1113-1120. PubMed ID: 36120814
[TBL] [Abstract][Full Text] [Related]
14. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Kim YJ; Kim YI
Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [
Zang J; Wang G; Zhao T; Liu H; Lin X; Yang Y; Shao Z; Wang C; Chen H; Chen Y; Zhu Z; Miao W; Chen X; Zhang J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):871-882. PubMed ID: 37864592
[TBL] [Abstract][Full Text] [Related]
17. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Wei X; Schlenkhoff C; Schwarz B; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2017 Sep; 42(9):704-706. PubMed ID: 28719450
[TBL] [Abstract][Full Text] [Related]
18. Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.
Seifert R; Kessel K; Boegemann M; Köhler M; Roll W; Stegger L; Weckesser M; Rahbar K
J Nucl Med; 2020 May; 61(5):723-728. PubMed ID: 31601703
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of
Gafita A; Fendler WP; Hui W; Sandhu S; Weber M; Esfandiari R; Calais J; Rauscher I; Rathke H; Tauber R; Delpassand ES; Weber WA; Herrmann K; Czernin J; Eiber M; Hofman MS
Eur Urol; 2020 Aug; 78(2):148-154. PubMed ID: 32532512
[TBL] [Abstract][Full Text] [Related]
20. Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer.
Satapathy S; Das CK; Parihar AS; Sood A; Mittal BR
Clin Nucl Med; 2021 Jul; 46(7):582-583. PubMed ID: 33630794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
